培美曲塞与贝伐单抗联合应用维持治疗晚期肺腺癌的临床疗效

doi:10.19739/j.cnki.issn1001-9510.2020.03.007

Abstract
Figure/Table
References
Related Citation (2)

Download: PDF (784 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To observe the clinical efficacy and side effects of pemetrexed combined with bevacizumab in the maintenance treatment of advanced lung adenocarcinoma.Methods Fifty-four patients with driver gene negative advanced lung adenocarcinoma received 4-6 cycles of first-line pemetrexed +/- bevacizumab + cisplatin chemotherapy. After the disease was controlled, they were divided into the pemetrexed + bevacizumab + cisplatin group and pemetrexed monotherapy group, and then the PFS, effective rate and adverse reactions of the two groups were observed. At the same time, fasting venous blood of patients before maintenance treatment and after 4 cycles of maintenance treatment was collected, and the vascular endothelial growth factor (VEGF) level was detected by ELISA to evaluate the correlation between changes in serum VEGF level and the efficacy.Results Both ORR and DCR of the two drug groups were significantly higher than those of the single drug group (P<0.05 or <0.01). The median PFS of two groups were 7.8 and 3.9 months and there was statistically significant difference between the two groups by log-rank test. After 4 cycles of maintenance treatment, the serum VEGF level of patients in the two groups significantly decreased after treatment, compared with VEGF level before treatment (P<0.01); compared with the single drug group, the serum VEGF level of patients in the two drug groups decreased significantly after treatment (P<0.01).Conclusion The combination of pemetrexed and bevacizumab in the maintenance treatment of advanced lung adenocarcinoma is more effective in the near term, with better efficacy and safety, and is worthy of clinical promotion. Meanwhile, dynamic monitoring of serum VEGF expression level can effectively predict the efficacy of anti-tumor therapy and is convenient and non-invasive.

Key words： lung adenocarcinoma cancer bevacizumab pemetrexed VEGF maintenance therapy

Received: 25 November 2019

PACS:

R734.2

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	WANG Peng
	LI Li

Cite this article:

WANG Peng,LI Li. The clinical efficacy of bevacizumab combined with pemetrexed in the maintenance treatment of advanced lung adenocarcinoma[J]. 滨州医学院学报, 2020, 43(3): 186-189.

URL:

http://manu58.magtech.com.cn/Jwk_bzyxy/EN/10.19739/j.cnki.issn1001-9510.2020.03.007 OR http://manu58.magtech.com.cn/Jwk_bzyxy/EN/Y2020/V43/I3/186

[1] FITZMAURICE C, DICKER D, PAIN A,et al. The global burden of cancer 2013[J]. JAMA Oncol, 2015, 1(4):505-527.
[2] RECK M, VON PAWEL J, ZATLOUKAL P,et al. Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous nonsmall-cell lung cancer: AVAiL[J]. J Clin Oncol, 2009, 27: 1227-1234.
[3] BARLESI F, SCHERPEREEL A, RITTMEYER A, et al. Randomized phase III trial of maintenance bevacizumab with or without pemetrexed after first-line induction with bevacizumab, cisplatin, and pemetrexed in advanced nonsquamous non-small-cell lung cancer: AVAPERL (MO22089) [J].J Clin Oncol,2013,31:3004-3011.
[4] AZZOLI C G, BAKER S J R, TEMIN S, et al. American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV non-small-cell lung cancer [J]. J Clin Oncol, 2009, 27(36): 6251-6266.
[5] ZHOU C, WU Y L, CHEN G, et al. BEYOND: a randomized, doubleblind, placebo-controlled, multicenter, phase Ⅲ study of first-line carboplatin/paclitaxel plus bevacizumab or placebo in Chinese patients with advanced or recurrent nonsquamous non- small- cell lung cancer[J]. J Clin Oncol, 2015, 33(19):2197-2204.
[6] 田宏,金锷.多西他赛联合贝伐珠单抗对比多西他赛单药二线治疗NSCLC的疗效和安全性[J].中国实用医药,2015,10(35):120-121.
[7] 黄毅超,刘云军,何宛谦,等.贝伐单抗联合化疗治疗晚期老年肺腺癌的临床疗效观察[J].实用癌症杂志, 2018, 33(7):1131-1134.
[8] TAKEDA M, YAMANAKA T, SETO T, et al. Bevacizumab beyond disease progression after first-line treatment with bevacizumab plus chemotherapy in advanced nonsquamous non- small cell lung cancer (west Japan oncology group 5910L): An open - label, randomized,phase Ⅱ trial[J]. Cancer, 2016, 122(7):1050-1059.
[9] BERGE E M, DOEBELE R C. Re-examination of maintenance therapy in non-small cell lung cancer with the advent of new anti-cancer agents[J]. Drugs,2013,73(6):517-532.
[10] 周英文,周玉福,张莉梅.培美曲塞或紫杉醇联合奈达铂一线治疗晚期肺腺癌临床评价[J]. 中国药业, 2017, 26( 12) : 53-55.
[11] ZINNER R G, OBASAJU C K, SPIGEL D R, et al. PRONOUNCE: randomized,open- label, phase Ⅲ study of first- line pemetrexed + carboplatin followed by maintenance pemetrexed versus paclitaxel+ carboplat in + bevacizumab followed by maintenance bevacizumab in patients with advanced nonsquamous non-small cell lung cancer[J]. J Thorac Oncol, 2015, 10(1):134-142.
[12] KARAYAMA M, INUI N, FUJISAWA T, et al. Maintenance therapy with pemetrexed and bevacizumab versus pemetrexed monotherapy after induction therapy with carboplatin, pemetrexed, and bevacizumab in patients with advanced non-squamous non small cell lung cancer[J]. Eur J Cancer, 2016, 58:30-37.
[13] ZHANG S, MAO X, WANG H, et al. Efficacy and safety of bevacizumab plus erlotinib versus bevacizumab or erlotinib alone in the treatment of non-small cell lung cancer: a systematic review and metaanalysis[J]. BMJ Open, 2016, 6(6):e011714.